Biogen Inc. Stock Underperforms Monday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Biogen Inc. (BIIB) shares fell 2.93% to $199.95 on Monday, underperforming competitors like Johnson & Johnson, Pfizer, and AbbVie during a broader market decline. This marks the second consecutive day of losses for Biogen, which remains 9% below its 52-week high. Trading volume was notably lower than the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Biogen Inc. (BIIB) slipped 2.93% to $199.95 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.19% to 7,443.28 and Dow Jones Industrial Average falling 0.59% to 51,839.26.
This was the stock's second consecutive day of losses.
Biogen Inc. closed 9.00% short of its 52-week high of $219.72, which the company achieved on June 29th.
The stock underperformed when compared to some of its competitors Monday, as Johnson & Johnson (JNJ) fell 1.67% to $248.82, Pfizer Inc. (PFE) fell 1.20% to $24.75, and AbbVie Inc. (ABBV) fell 0.44% to $253.38.
Trading volume (962,629) remained 342,178 below its 50-day average volume of 1.3 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 20, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-20-26 1658ET